Dergiler / Turkish Journal of Gastroenterology / 2017 / Cilt: 28 - Sayı: 1

Mean arterial pressure drop is an independent risk factor of death in patients with HBV-related cirrhosis ascites

Sayfa
26–30
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

MAP may be used for determining the prognosis and exploring new treatment measures directed at optimizing the treatment of liver cirrhosis ascites.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/Aims: In patients with cirrhosis ascites, mean arterial pressure (MAP) is a credible sign of circulatory dysfunction.
📊
Temel Bulgular & Veri:Materials and Methods: In total, 110 patients of HBV-related liver cirrhosis ascites were prospectively followed for 5 years.
💡
Sonuç & Katkı:MAP may be used for determining the prognosis and exploring new treatment measures directed at optimizing the treatment of liver cirrhosis ascites.
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Background/Aims: In patients with cirrhosis ascites, mean arterial pressure (MAP) is a credible sign of circulatory dysfunction. There are no studies on the relationship between MAP and long-term prognosis in hepatitis B virus (HBV)-related liver cirrhosis ascites. Therefore, we assessed the association between MAP and prognosis in patients with liver cirrhosis ascites. Materials and Methods: In total, 110 patients of HBV-related liver cirrhosis ascites were prospectively followed for 5 years. After their admission, the patients underwent laboratory tests and MAP measurements. Multivariate analysis was conducted using backward stepwise Cox proportional hazards regression. Receiver operator characteristic (ROC) curves were used to confirm the best cutoff value of several baseline parameters, including MAP, for predicting death in patients with liver cirrhosis ascites. Results: In a follow-up period of 5 years, 60 (54.5%) patients survived. MAP (OR 1.176, 95% CI 1.045 to 1.326, p=0.003) was an independent risk factor of death, together with Child-Pugh score (OR 1.204, 95% CI 1.068 to 1.357, p=0.002) and model for end-stage liver disease score (OR 1.297, 95% CI 1.198 to 1.405, p=0.000). The area under the ROC curve of MAP was 0.819 at baseline (95% CI 0.741 to 0.897, p=0.000). A baseline MAP value of <=83.5 mmHg was an independent risk factor of death. Conclusion: A decrease in MAP was a valuable predictor of death in patients with HBV-related liver cirrhosis ascites. MAP may be used for determining the prognosis and exploring new treatment measures directed at optimizing the treatment of liver cirrhosis ascites.

🔖

Bu Makaleye Atıf Yap

Lİ, H., GUO, Z., YANG, X. Y., SUN, D. X. (2017). Mean arterial pressure drop is an independent risk factor of death in patients with HBV-related cirrhosis ascites. Turkish Journal of Gastroenterology, Cilt: 28 - Sayı: 1, 26–30. https://ajindex.com/articles/410186

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Becker E. Diagnosis and therapy of ascites in liver cirrhosis. World J Gastroenterol 2011
  2. [CrossRef] D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognos- tic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006
  3. [CrossRef] Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014
  4. [CrossRef] Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatol- ogy 2009
  5. [CrossRef] Llach J, Gines P, Arroyo V, et al. Prognostic value of arterial pres- sure, endogenous vasoactive systems, and renal function in cir- rhotic patients admitted to the hospital for the treatment of asci- tes. Gastroenterology 1988
  6. [CrossRef] Xu JY, Ma SQ, Pan C, et al. A high mean arterial pressure target is associated with improved microcirculation in septic shock patients with previous hypertension: a prospective open label study. Crit Care 2015
  7. [CrossRef] Gomez EV, Rodriguez YS, Bertot LC, et al. The natural history of compensated HCV-related cirrhosis: A prospective longterm study. J Hepatol 2013
  8. [CrossRef] Thooft A, Favory R, Salgado DR, et al. Effects of changes in arterial pressure on organ perfusion during septic shock. Crit Care 2011
  9. R222. Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut 2006
  10. 55(Suppl 6): vi1-12. Moore CM, Van Thiel DH. Cirrhotic ascites review: Pathophysiol- ogy, diagnosis and management. World J Hepatol 2013
  11. [CrossRef] Lenz K, Buder R, Kapun L, Voqlmayr M. Treatment and manage- ment of ascites and hepatorenal syndrome: an update. Therap Adv Gastroenterol 2015
  12. [CrossRef] Mİller S, Hobolth L, Winkler C, Bendtsen F, Christensen E. Deter- minants of the hyperdynamic circulation and central hypovolae- mia in cirrhosis. Gut 2011
  13. [CrossRef] Henriksen JH, Fuglsang S, Bendtsen F, Mİller S. Arterial hyperten- sion in cirrhosis: arterial compliance, volume distribution, and central haemodynamics. Gut 2006
  14. [CrossRef] Wallerstedt S, Simrén M, Wahlin S, et al. Moderate hyperkalemia in hospitalized patients with cirrhotic ascites indicates a poor prog- nosis. Scand J Gastroenterol 2013
  15. [CrossRef] Maiwall R, Kumar S, Sharma MK, Wani Z, Ozukum M, Sarin SK. Prevalence and prognostic significance of hyperkalemia in hos- pitalized patients with cirrhosis. J Gastroenterol Hepa